Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
Jonathan L. Curry, Michael T. Tetzlaff, Priyadharsini Nagarajan, et al.
Journal of Cutaneous Pathology (2016) Vol. 44, Iss. 2, pp. 158-176
Open Access | Times Cited: 214

Showing 1-25 of 214 citing articles:

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
John B.A.G. Haanen, Franck Carbonnel, Caroline Robert, et al.
Annals of Oncology (2017) Vol. 28, pp. iv119-iv142
Open Access | Times Cited: 2147
A review of cancer immunotherapy toxicity
Lucy Boyce Kennedy, April K.S. Salama
CA A Cancer Journal for Clinicians (2020) Vol. 70, Iss. 2, pp. 86-104
Open Access | Times Cited: 1107
Dermatologic Reactions to Immune Checkpoint Inhibitors
V. Sibaud
American Journal of Clinical Dermatology (2017) Vol. 19, Iss. 3, pp. 345-361
Closed Access | Times Cited: 507
Immune checkpoint inhibitor–related dermatologic adverse events
Amaris Geisler, Gregory S. Phillips, Dulce M. Barrios, et al.
Journal of the American Academy of Dermatology (2020) Vol. 83, Iss. 5, pp. 1255-1268
Open Access | Times Cited: 340
Implications of the tumor immune microenvironment for staging and therapeutics
Janis M. Taube, Jérôme Galon, Lynette M. Sholl, et al.
Modern Pathology (2017) Vol. 31, Iss. 2, pp. 214-234
Open Access | Times Cited: 325
Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls
Eli P. Darnell, Meghan J. Mooradian, Erez N. Baruch, et al.
Current Oncology Reports (2020) Vol. 22, Iss. 4
Closed Access | Times Cited: 309
Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors
Juwhan Choi, Sung Yong Lee
Immune Network (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 215
Treatment Outcomes of Immune-Related Cutaneous Adverse Events
Gregory S. Phillips, Jennifer Wu, Matthew D. Hellmann, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 30, pp. 2746-2758
Open Access | Times Cited: 197
Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy
Jacob Siegel, Mariam Totonchy, William Damsky, et al.
Journal of the American Academy of Dermatology (2018) Vol. 79, Iss. 6, pp. 1081-1088
Closed Access | Times Cited: 186
Immune-related adverse events in various organs caused by immune checkpoint inhibitors
Naoko Okiyama, Ryota Tanaka
Allergology International (2022) Vol. 71, Iss. 2, pp. 169-178
Open Access | Times Cited: 82
Cutaneous manifestations associated with immune checkpoint inhibitors
Tomoya Watanabe, Yukie Yamaguchi
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 51
Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management
Emily Coleman, Christine J. Ko, Feng Dai, et al.
Journal of the American Academy of Dermatology (2018) Vol. 80, Iss. 4, pp. 990-997
Open Access | Times Cited: 150
Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies
Chun‐Bing Chen, Ming-Ying Wu, Chau Yee Ng, et al.
Cancer Management and Research (2018) Vol. Volume 10, pp. 1259-1273
Open Access | Times Cited: 138
Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients
Michael T. Tetzlaff, Kelly C. Nelson, Adi Diab, et al.
Journal for ImmunoTherapy of Cancer (2018) Vol. 6, Iss. 1
Open Access | Times Cited: 137
Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features
Samantha R. Ellis, Aren T. Vierra, Jillian Wong Millsop, et al.
Journal of the American Academy of Dermatology (2020) Vol. 83, Iss. 4, pp. 1130-1143
Open Access | Times Cited: 133
IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy
Daniel H. Johnson, Anisha B. Patel, Marc Uemura, et al.
Cancer Immunology Research (2019) Vol. 7, Iss. 6, pp. 860-865
Open Access | Times Cited: 95
Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy
Leo Wang, Gopal Patel, Zelma C. Chiesa Fuxench, et al.
JAMA Dermatology (2018) Vol. 154, Iss. 9, pp. 1057-1057
Open Access | Times Cited: 92
Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis
Shannon Wongvibulsin, Vartan Pahalyants, Mark Kalinich, et al.
Journal of the American Academy of Dermatology (2021) Vol. 86, Iss. 3, pp. 563-572
Open Access | Times Cited: 78
European recommendations for management of immune checkpoint inhibitors‐derived dermatologic adverse events. The EADV task force ‘Dermatology for cancer patients’ position statement
Zoé Apalla, Vasiliki Nikolaou, Davide Fattore, et al.
Journal of the European Academy of Dermatology and Venereology (2021) Vol. 36, Iss. 3, pp. 332-350
Open Access | Times Cited: 65
Immunotherapy toxicity: identification and management
Özge Gümüşay, John F. Callan, Hope S. Rugo
Breast Cancer Research and Treatment (2022) Vol. 192, Iss. 1, pp. 1-17
Open Access | Times Cited: 56
Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota
Zishuo Ian Hu, Verena M. Link, Djalma S. Lima-Júnior, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 26
Open Access | Times Cited: 46
Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article
Chieh‐Hsun Chen, Hsin‐Su Yu, Sebastian Yu
Current Oncology (2022) Vol. 29, Iss. 4, pp. 2871-2886
Open Access | Times Cited: 41
Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors
Yi-Shan Teng, Sebastian Yu
Current Oncology (2023) Vol. 30, Iss. 7, pp. 6805-6819
Open Access | Times Cited: 24
Toxicity in the era of immune checkpoint inhibitor therapy
Synat Keam, Naimah Turner, Fernanda G. Kugeratski, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 14
Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy
Jingjing Su, Yiting Fu, Zitong Cui, et al.
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top